title: Risk of contralateral second primary breast cancer according to hormone receptor status in Germany.
abstract: BACKGROUND
  Hormone receptor (HR) status has become an established target in treatment strategies of breast cancer. Population-based estimates of contralateral breast cancer (CBC) incidence by HR subtype in particular are limited. The aim of this study was to provide detailed data on CBC incidence for Germany.
  
  
  METHODS
  Invasive breast cancer data were extracted on 49,804 women yielding 594 second primaries from the cancer registries of the Federal States of Brandenburg and Saarland and the area of Munich for the period from 1998 to 2007. Multiple imputation was used on missing values for HR status. We estimated standardized incidence ratios (SIRs) with 95% confidence intervals (95%CIs).
  
  
  RESULTS
  SIR estimates of CBC among women diagnosed with an invasive first primary breast cancer (FBC) of any HR subtype ranged from 1.0 to 1.5 in the three registries. Pooling three registries' data, the SIR of HR-positive CBC was 0.7 (95%CI: 0.6 to 0.8) among women with HR-positive FBC. For those women with HR-negative FBC, the SIR of HR-negative CBC was 8.9 (95%CI: 7.1 to 11.1). Among women with FBC diagnosed before the age of 50 years, incidence of CBC was increased, especially for HR-negative FBC (SIR: 9.2; 95%CI: 7.1 to 11.9).
  
  
  CONCLUSIONS
  HR status of the first primary and age at first diagnosis is relevant for predicting risk of CBC. Particularly, patients with HR-negative FBC had elevated risks.
authors.forename: Carsten
authors.initials: C
authors.lastname: Rusner
authors.forename: Katharina
authors.initials: K
authors.lastname: Wolf
authors.forename: Ulrike
authors.initials: U
authors.lastname: Bandemer-Greulich
authors.forename: Jutta
authors.initials: J
authors.lastname: Engel
authors.forename: Christa
authors.initials: C
authors.lastname: Stegmaier
authors.forename: Bernd
authors.initials: B
authors.lastname: Holleczek
authors.forename: Gabriele
authors.initials: G
authors.lastname: Schubert-Fritschle
authors.forename: Anett
authors.initials: A
authors.lastname: Tillack
authors.forename: Andreas
authors.initials: A
authors.lastname: Stang
mesh_terms: D000368:Aged; D001943:Breast Neoplasms / Q000453:epidemiology* / Q000378:metabolism; D018270:Carcinoma, Ductal, Breast / Q000453:epidemiology* / Q000378:metabolism; D018275:Carcinoma, Lobular / Q000453:epidemiology* / Q000378:metabolism; D005260:Female; D005858:Germany / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000453:epidemiology* / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012306:Risk
chemical_list: D011960:Receptors, Estrogen; D011980:Receptors, Progesterone